Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Prognostic Value of Circulating H3K27Me3-Nucleosomes In Newly Diagnosed Lung Cancer Patients

Monday, December 8, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The poster presented at NACLC 2025 discusses the prognostic value of circulating H3K27Me3-nucleosomes in newly diagnosed lung cancer patients. This research could enhance early detection and patient management. The findings are linked to the Nu.Q® cancer test, which shows promise in improving prognostic assessments.
Price reaction · baseline $5.994 (2025-12-05 close) · hit pre-market · 4 other VNRX headline(s) in the window, move may be shared
day 0 close
-0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation highlights a novel prognostic marker for lung cancer.
  • Potential to improve patient outcomes through early detection.
  • Research presented at a significant conference (NACLC 2025).

Full Press Release Details

Poster titled: Prognostic Value of Circulating H3K27Me3-Nucleosomes In Newly Diagnosed Lung Cancer Patients
M. Piecyk, A. Kotronoulas, J. Candiracci, E. Grolleau, G. Lescuyer, F. Wuilque, S. Couraud, M. Herzog, L. Payen
Presented at NACLC 2025

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the poster presented at NACLC 2025?

The poster focuses on the prognostic value of circulating H3K27Me3-nucleosomes in newly diagnosed lung cancer patients.

How could H3K27Me3-nucleosomes impact lung cancer treatment?

These nucleosomes may improve early detection and patient management in lung cancer.

What is the Nu.Q® cancer test?

The Nu.Q® cancer test is linked to the research on H3K27Me3-nucleosomes and aims to enhance prognostic assessments.

Who are the authors of the poster?

The poster was authored by M. Piecyk, A. Kotronoulas, J. Candiracci, and others.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare lung cancer H3K27Me3 Nu.Q® cancer test NACLC 2025 prognostic marker
Last updated: Dec 8, 2025

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk